A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Vorinostat (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- 18 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 18 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 15 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2017, as reported by ClinicalTrials.gov record.